blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2531172

EP2531172 - PHARMACEUTICAL COMPOSITION WITH ANTI-OBESITY ACTIVITY COMPRISING A PREMIXTURE OF PURE ORLISTAT AND PREPARATION PROCESS [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  18.08.2017
Database last updated on 09.09.2024
Most recent event   Tooltip15.11.2019Lapse of the patent in a contracting state
New state(s): MK		published on 18.12.2019  [2019/51]
Applicant(s)For all designated states
Laboratorios Bagó S.A.
Bernardo de Irigoyen 248
1072 Buenos Aires / AR
For all designated states
Eastbrand Holding GmbH
Börseplatz 4
1010 Wien / AT
[2016/41]
Former [2012/50]For all designated states
Laboratorios Bagó S.A.
Bernardo de Irigoyen 248
C1072AAF Buenos Aires / AR
For all designated states
Eastbrand Holding GmbH
Börseplatz 4
1010 Wien / AT
Inventor(s)01 / LOS, Mario, Atilio
Bernardo de Irigoyen 248
1072 Buenos Aires / AR
 [2012/50]
Representative(s)Curell Suñol S.L.P.
Muntaner 240, 4º 2ª
08021 Barcelona / ES
[N/P]
Former [2013/32]Curell Suñol S.L.P.
Via Augusta 21
08006 Barcelona / ES
Former [2012/50]Curell Suñol, Jorge
Curell Suñol S.L.P.
Passeig de Gràcia 65 bis
ES-08008 Barcelona / ES
Application number, filing date10709955.801.02.2010
[2016/41]
WO2010EP00579
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2011091816
Date:04.08.2011
Language:EN
[2011/31]
Type: A1 Application with search report 
No.:EP2531172
Date:12.12.2012
Language:EN
The application published by WIPO in one of the EPO official languages on 04.08.2011 takes the place of the publication of the European patent application.
[2012/50]
Type: B1 Patent specification 
No.:EP2531172
Date:12.10.2016
Language:EN
[2016/41]
Search report(s)International search report - published on:EP04.08.2011
ClassificationIPC:A61K9/00, A61K9/14, A61K9/16, A61K31/365, A61K9/20
[2012/50]
CPC:
A61K9/145 (EP,US); A61K31/365 (EP,US); A61K9/0095 (EP,US);
A61K9/2018 (EP,US); A61K9/2054 (EP,US); A61K9/282 (EP,US);
A61K9/286 (EP,US); A61P3/00 (EP); A61P3/04 (EP);
A61K9/5084 (EP,US) (-)
Designated contracting statesAT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   SE,   SI,   SK,   SM,   TR [2012/50]
Extension statesALNot yet paid
BANot yet paid
RSNot yet paid
TitleGerman:PHARMAZEUTISCHE ZUSAMMENSETZUNG GEGEN FETTLEIBIGKEIT MIT EINER VORMISCHUNG AUS REINEM ORLISTAT UND HERSTELLUNGSVERFAHREN[2012/50]
English:PHARMACEUTICAL COMPOSITION WITH ANTI-OBESITY ACTIVITY COMPRISING A PREMIXTURE OF PURE ORLISTAT AND PREPARATION PROCESS[2012/50]
French:COMPOSITION PHARMACEUTIQUE AYANT UNE ACTIVITÉ ANTI-OBÉSITÉ ET COMPRENANT UN PRÉ-MÉLANGE D'ORLISTAT PUR ET PROCÉDÉ DE PRÉPARATION DE CELLE-CI[2012/50]
Entry into regional phase16.07.2012National basic fee paid 
16.07.2012Designation fee(s) paid 
16.07.2012Examination fee paid 
Examination procedure16.07.2012Examination requested  [2012/50]
27.03.2013Amendment by applicant (claims and/or description)
20.06.2016Communication of intention to grant the patent
31.08.2016Fee for grant paid
31.08.2016Fee for publishing/printing paid
31.08.2016Receipt of the translation of the claim(s)
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  20.06.2016
Opposition(s)13.07.2017No opposition filed within time limit [2017/38]
Fees paidRenewal fee
17.07.2012Renewal fee patent year 03
10.12.2012Renewal fee patent year 04
04.12.2013Renewal fee patent year 05
07.01.2015Renewal fee patent year 06
29.12.2015Renewal fee patent year 07
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU01.02.2010
CY12.10.2016
CZ12.10.2016
DK12.10.2016
EE12.10.2016
FI12.10.2016
HR12.10.2016
LT12.10.2016
LV12.10.2016
MC12.10.2016
MK12.10.2016
NL12.10.2016
RO12.10.2016
SE12.10.2016
SI12.10.2016
SK12.10.2016
SM12.10.2016
BG12.01.2017
NO12.01.2017
LU01.02.2017
MT01.02.2017
IS12.02.2017
PT13.02.2017
[2019/51]
Former [2019/46]HU01.02.2010
CY12.10.2016
CZ12.10.2016
DK12.10.2016
EE12.10.2016
FI12.10.2016
HR12.10.2016
LT12.10.2016
LV12.10.2016
MC12.10.2016
NL12.10.2016
RO12.10.2016
SE12.10.2016
SI12.10.2016
SK12.10.2016
SM12.10.2016
BG12.01.2017
NO12.01.2017
LU01.02.2017
MT01.02.2017
IS12.02.2017
PT13.02.2017
Former [2019/31]HU01.02.2010
CZ12.10.2016
DK12.10.2016
EE12.10.2016
FI12.10.2016
HR12.10.2016
LT12.10.2016
LV12.10.2016
MC12.10.2016
NL12.10.2016
RO12.10.2016
SE12.10.2016
SI12.10.2016
SK12.10.2016
SM12.10.2016
BG12.01.2017
NO12.01.2017
LU01.02.2017
MT01.02.2017
IS12.02.2017
PT13.02.2017
Former [2018/43]CZ12.10.2016
DK12.10.2016
EE12.10.2016
FI12.10.2016
HR12.10.2016
LT12.10.2016
LV12.10.2016
MC12.10.2016
NL12.10.2016
RO12.10.2016
SE12.10.2016
SI12.10.2016
SK12.10.2016
SM12.10.2016
BG12.01.2017
NO12.01.2017
LU01.02.2017
MT01.02.2017
IS12.02.2017
PT13.02.2017
Former [2018/04]CZ12.10.2016
DK12.10.2016
EE12.10.2016
FI12.10.2016
HR12.10.2016
LT12.10.2016
LV12.10.2016
MC12.10.2016
NL12.10.2016
RO12.10.2016
SE12.10.2016
SI12.10.2016
SK12.10.2016
SM12.10.2016
BG12.01.2017
NO12.01.2017
LU01.02.2017
IS12.02.2017
PT13.02.2017
Former [2017/52]CZ12.10.2016
DK12.10.2016
EE12.10.2016
FI12.10.2016
HR12.10.2016
LT12.10.2016
LV12.10.2016
MC12.10.2016
NL12.10.2016
RO12.10.2016
SE12.10.2016
SI12.10.2016
SK12.10.2016
SM12.10.2016
BG12.01.2017
NO12.01.2017
IS12.02.2017
PT13.02.2017
Former [2017/42]CZ12.10.2016
DK12.10.2016
EE12.10.2016
FI12.10.2016
HR12.10.2016
LT12.10.2016
LV12.10.2016
MC12.10.2016
NL12.10.2016
RO12.10.2016
SE12.10.2016
SK12.10.2016
SM12.10.2016
BG12.01.2017
NO12.01.2017
IS12.02.2017
PT13.02.2017
Former [2017/38]CZ12.10.2016
DK12.10.2016
EE12.10.2016
FI12.10.2016
HR12.10.2016
LT12.10.2016
LV12.10.2016
NL12.10.2016
RO12.10.2016
SE12.10.2016
SK12.10.2016
SM12.10.2016
BG12.01.2017
NO12.01.2017
IS12.02.2017
PT13.02.2017
Former [2017/35]CZ12.10.2016
DK12.10.2016
EE12.10.2016
FI12.10.2016
HR12.10.2016
LT12.10.2016
LV12.10.2016
NL12.10.2016
RO12.10.2016
SE12.10.2016
NO12.01.2017
IS12.02.2017
PT13.02.2017
Former [2017/34]CZ12.10.2016
DK12.10.2016
FI12.10.2016
HR12.10.2016
LT12.10.2016
LV12.10.2016
NL12.10.2016
SE12.10.2016
NO12.01.2017
IS12.02.2017
PT13.02.2017
Former [2017/33]DK12.10.2016
FI12.10.2016
HR12.10.2016
LT12.10.2016
LV12.10.2016
NL12.10.2016
SE12.10.2016
NO12.01.2017
IS12.02.2017
PT13.02.2017
Former [2017/26]FI12.10.2016
HR12.10.2016
LT12.10.2016
LV12.10.2016
NL12.10.2016
SE12.10.2016
NO12.01.2017
IS12.02.2017
PT13.02.2017
Former [2017/12]LV12.10.2016
Cited inInternational search[ID]US6004996  (SHAH NAVNIT HARGOVINDAS [US], et al) [ID] 1-25 * example -; claim - * * tables 3-5 ** claim - *;
 [X]US2006246141  (LIVERSIDGE GARY G [US], et al) [X] 1-6,8,12-25 * paragraphs [0077] , [ 102] - [0111] *;
 [X]WO2009044380  (RANBAXY LAB LTD [IN], et al) [X] 1-25 * page 3, lines 8-18 * * page 4, line 18 - page 5, line 2 * * examples 1-5 * * claim - *;
 [I]WO2009116880  (ZAKLADY FARM POLPHARMA SA [PL], et al) [I] 1-25 * page 2, lines 13-19 * * page 4, line 7 - page 5, line 2 * * examples 1-6 * * claim - *
by applicantUS3923976
 EP0129748
 US4598089
 US6004996
 AR010704
 AR025609
 US6703369
    - STALDER HENRI; SCHNEIDER PIERRE; GOTTFRIED OESTERHELT, "Tetrahydrolipstatin: Thermal and Hydrolytic Degradation", HELVETICA CHIMICA ACTA, (1990), vol. 73, pages 1022 - 1035
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.